Phaseline

Companies › Pilatus Biosciences

Pilatus Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PLT012
anti-CD36 monoclonal antibody
CD36Phase 1Advanced Malignant Solid TumorSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07337525PLT012Phase 1Advanced Malignant Solid TumorOncologySep 2027

Targets

CD36 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.